Amgen EPO Claims Monitoring To Include Dosing Levels – CMS Draft Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed revision would replace current policy of targeting physicians whose patients have average hematocrit levels over 37.5%. New policy would review erythropoietin claims with high hematocrit/hemoglobin levels and high doses.